Comprehensive clinical development programs being initiated for each investigational candidate
The product is expected to be launched in December 2023
Cresemba is the only azole antifungal therapy approved for pediatric patients as young as one affected by these serious, potentially life-threatening infections
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Proposed combination enhances Pfizer’s position as a leading company in oncology
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
The investment will accelerate the overall Sarclisa development program
Subscribe To Our Newsletter & Stay Updated
